Last updated on May 2019

Effect of Efpeglenatide on Cardiovascular Outcomes


Brief description of study

Primary Objective:

-To demonstrate that, efpeglenatide doses 1 and 2 is noninferior to placebo on 3-point major adverse cardiac event (MACE) in Type 2 diabetes mellitus (T2DM) patients at high cardiovascular (CV) risk.

Secondary Objectives:

  • To demonstrate that efpeglenatide doses 1 and 2 is superior to placebo in T2DM patients with high CV risk on the following parameters:
  • 3-point MACE.
  • Expanded CV outcome.
  • Composite outcome of new or worsening nephropathy.
  • To assess the safety and tolerability of efpeglenatide doses 1 and 2, both added to standard of care in T2DM patients at high CV risk.

Detailed Study Description

The estimated study duration per participant is up to approximately 36 months.

Clinical Study Identifier: NCT03496298

Find a site near you

Start Over

Investigational Site Number 8400022

Beverly Hills, CA United States
  Connect »

Investigational Site Number 8400003

Mission Hills, CA United States
  Connect »

Investigational Site Number 8400041

New Port Richey, FL United States
  Connect »

Investigational Site Number 8400095

Arlington Heights, IL United States
  Connect »

Investigational Site Number 8400056

Staten Island, NY United States
  Connect »

Investigational Site Number 8400007

Morehead City, NC United States
  Connect »

Investigational Site Number 8400093

Morehead City, NC United States
  Connect »

Investigational Site Number 8400063

Murrells Inlet, SC United States
  Connect »

Investigational Site Number 8400055

Corpus Christi, TX United States
  Connect »

Investigational Site Number 8400039

Salt Lake City, UT United States
  Connect »

Investigational Site Number 2760007

Rotenburg An Der Fulda, Germany
  Connect »

Investigational Site Number 4100006

Guri-Si, Gyeonggi-Do, Korea, Republic of
  Connect »

Investigational Site Number 6430006

Saint-Petersburg, Russian Federation
  Connect »

Investigational Site Number 6430017

Krasnogorsk, Russian Federation
  Connect »

Investigational Site Number 6430019

Novosibirsk, Russian Federation
  Connect »

Investigational Site Number 6430018

Kaliningrad, Russian Federation
  Connect »

Investigational Site Number 6430012

Saint-Petersburg, Russian Federation
  Connect »

Investigational Site Number 6430010

St-Petersburg, Russian Federation
  Connect »

Investigational Site Number 6430016

St. Petersburg, Russian Federation
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.